% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cui:303240,
      author       = {Z. Cui$^*$ and L. Schomburg and B. Holleczek and S. Hybsier
                      and J. Köhrle and H. Brenner$^*$ and B. Schöttker$^*$},
      title        = {{S}erum selenoprotein {P} concentrations and cardiovascular
                      disease: results from a large, prospective cohort study of
                      older {G}erman adults.},
      journal      = {Free radical biology and medicine},
      volume       = {239},
      issn         = {0891-5849},
      address      = {New York, NY [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01586},
      pages        = {270-279},
      year         = {2025},
      note         = {#EA:C070#LA:C070# / Volume 239, November 2025, Pages
                      270-279},
      abstract     = {Studies on the association of selenoprotein P (SELENOP)
                      with cardiovascular outcomes yielded inconsistent results.
                      We assessed the association of SELENOP serum levels with
                      cardiovascular disease (CVD), stroke and coronary heart
                      disease (CHD) in CVD-free adults and the association with
                      CVD mortality in CVD patients.Serum SELENOP concentrations
                      were measured at baseline and 5-year follow-up in 6,600
                      CVD-free participants and 1,729 CVD patients aged 50-74
                      years from the German ESTHER study. Multivariable Cox models
                      were performed.During 17 years of follow-up, 1,837 CVD-free
                      participants developed CVD, of whom 675 had a stroke and
                      1,153 were diagnosed with CHD, and 352 CVD patients died
                      from CVD. In the multivariable Cox model, CVD-free
                      participants in the lowest SELENOP quartile had a 1.5-fold
                      higher stroke risk than those in the highest quartile (HR
                      $[95\%CI],$ 1.58 [1.17-2.12]). Associations with CVD
                      incidence were only observed in patients with hypertension
                      (HR $[95\%CI],$ 1.21 [1.03-1.41]) or diabetes (HR
                      $[95\%CI],$ 1.36 [1.01-1.83]). No association was observed
                      between SELENOP concentrations and CHD incidence.
                      Furthermore, CVD patients in the lowest SELENOP quartile had
                      an almost 2-fold increased CVD mortality compared to the
                      rest (HR $[95\%CI],$ 1.85 [1.31-2.60]).Low serum SELENOP
                      concentrations were associated with an increased risk of
                      stroke in subjects free of CVD and with CVD mortality among
                      CVD patients. The association of SELENOP concentrations with
                      CVD incidence was restricted to patients with hypertension
                      or diabetes. Well-designed trials are required to assess
                      potential preventive effects of selenium supplementation.},
      keywords     = {Cardiovascular Diseases (Other) / Cohort Studies (Other) /
                      Coronary Disease (Other) / Mortality (Other) / Selenoprotein
                      P (Other) / Stroke (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40738180},
      doi          = {10.1016/j.freeradbiomed.2025.07.039},
      url          = {https://inrepo02.dkfz.de/record/303240},
}